Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 3:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Unresectable or Metastatic Melanoma, Progressive Brain Metastasis
Interventions
HBI-8000 in combination with nivolumab, Placebo in combination with nivolumab
Drug
Lead sponsor
HUYABIO International, LLC.
Industry
Eligibility
12 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
31
States / cities
Bakersfield, California • La Jolla, California • Pasadena, California + 28 more
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
PLN-74809, Placebo
Drug
Lead sponsor
Pliant Therapeutics, Inc.
Industry
Eligibility
40 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
79
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 69 more
Conditions
Generalized Anxiety Disorder
Interventions
PF-06372865.
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
47
States / cities
Cerritos, California • Encino, California • Imperial, California + 41 more
Completed Not applicable Interventional Results available

REVEAL AF: Incidence of AF in High Risk Patients

NCT01727297
Conditions
Atrial Fibrillation
Interventions
REVEAL Implantable Cardiac Monitor
Device
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Industry
Eligibility
18 Years and older
Enrollment
446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
43
States / cities
Glendale, Arizona • Fresno, California • Palm Springs, California + 37 more
Conditions
Depressive Disorder, Major
Interventions
Placebo, JNJ-42847922
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
33
States / cities
Anaheim, California • Chino, California • Lemon Grove, California + 24 more
Conditions
Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
Interventions
Adagrasib, Pembrolizumab
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
626 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
220
States / cities
Goodyear, Arizona • Prescott Valley, Arizona • Safford, Arizona + 168 more
Conditions
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Synchronous Bilateral Breast Carcinoma, Anatomic Stage I Breast Cancer AJCC v8
Interventions
Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment
Biological · Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
1,056 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2035
U.S. locations
1160
States / cities
Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 749 more
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
SPN-810 (18 mg), SPN-810 (36 mg), Placebo
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 12 Years
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
28
States / cities
Rogers, Arkansas • Culver City, California • Glendale, California + 22 more
Conditions
Non-small Cell Lung Cancer
Interventions
M7824, Pembrolizumab
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
25
States / cities
Huntsville, Alabama • Los Angeles, California • Orange, California + 21 more
Active, not recruiting Phase 3 Interventional

Intravesical BCG vs GEMDOCE in NMIBC

NCT05538663
Conditions
Non-muscle-invasive Bladder Cancer
Interventions
Gemcitabine, Docetaxel, Bacillus Calmette Guerin
Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
870 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
229
States / cities
Birmingham, Alabama • Fairbanks, Alaska • Gilbert, Arizona + 163 more
Conditions
Non-Small Cell Lung Cancer
Interventions
Livmoniplimab, Budigalimab, Pembrolizumab, Pemetrexed, Cisplatin, Carboplatin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
19
States / cities
La Jolla, California • Pembroke Pines, Florida • Winter Haven, Florida + 16 more
Conditions
Bipolar Disorder
Interventions
placebo oral capsules, ziprasidone oral capsules
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
46
States / cities
Dothan, Alabama • Little Rock, Arkansas • Anaheim, California + 30 more
Conditions
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer, Carcinoma, Squamous Cell of Head and Neck
Interventions
tisotumab vedotin, pembrolizumab, carboplatin, cisplatin
Drug
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
124
States / cities
Encinitas, California • La Jolla, California • Sacramento, California + 57 more
Conditions
Diabetic Macular Edema
Interventions
RO7446603, Aflibercept, Faricimab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
70
States / cities
Phoenix, Arizona • Springdale, Arkansas • Campbell, California + 60 more
Conditions
Macular Degeneration
Interventions
Abicipar Pegol, Ranibizumab, Sham Procedure
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
50 Years and older
Enrollment
939 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
71
States / cities
Phoenix, Arizona • Tucson, Arizona • Encino, California + 61 more
Conditions
Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms, Neoplasms by Site, Digestive System Diseases, Gastrointestinal Diseases, Colonic Diseases, Intestinal Diseases, Rectal Diseases, Colorectal Neoplasms
Interventions
PF-08634404, Bevacizumab, Chemotherapy
Drug · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
181
States / cities
Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 148 more
Conditions
Metastatic Urothelial Cancer
Interventions
Sacituzumab Govitecan-hziy, Pembrolizumab, Cisplatin, Avelumab, Zimberelimab, Carboplatin, Gemcitabine, Domvanalimab, Enfortumab Vedotin
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
827 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
37
States / cities
Tucson, Arizona • Los Angeles, California • San Francisco, California + 32 more
Conditions
Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hypopharyngeal Squamous Cell Carcinoma, Advanced Laryngeal Squamous Cell Carcinoma, Advanced Oropharyngeal Squamous Cell Carcinoma, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions
Cisplatin, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy
Drug · Procedure · Other + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
1,714 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
361
States / cities
Mobile, Alabama • Jonesboro, Arkansas • Little Rock, Arkansas + 264 more
Conditions
Irritability Associated With Autism Spectrum Disorder
Interventions
Brexpiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
5 Years to 17 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
28
States / cities
Dothan, Alabama • Phoenix, Arizona • San Francisco, California + 24 more
Conditions
Renal Cell Carcinoma
Interventions
Lenvatinib, Everolimus, Pembrolizumab, Sunitinib
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,069 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
35
States / cities
Stanford, California • Boca Raton, Florida • Fort Myers, Florida + 29 more
Completed No phase listed Observational

CemiplimAb Survivorship Epidemiology

NCT03836105
Conditions
Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma
Interventions
cemiplimab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
51
States / cities
Huntsville, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 44 more
Conditions
Breast Cancer
Interventions
anastrozole, everolimus, exemestane, goserelin acetate, letrozole, leuprolide acetate, tamoxifen citrate, placebo
Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
1,939 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2030
U.S. locations
1455
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 887 more
Conditions
Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo
Interventions
Ritlecitinib, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,571 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
68
States / cities
Scottsdale, Arizona • Bryant, Arkansas • Fountain Valley, California + 47 more
Conditions
Lupus Erythematosus, Systemic
Interventions
Litifilimab, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
548 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
53
States / cities
Homewood, Alabama • Beverly Hills, California • Los Angeles, California + 46 more